Evaluating Candidate Principal Surrogate Endpoints
From MaRDI portal
Recommendations
- The Evaluation of Multiple Surrogate Endpoints
- The evaluation of surrogate endpoints.
- Comparing biomarkers as principal surrogate endpoints
- Criteria for Surrogate End Points
- Principal causal effect identification and surrogate end point evaluation by multiple trials
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- Criteria for Surrogate end Points Based on Causal Distributions
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
Cites work
- A case-cohort design for epidemiologic cohort studies and disease prevention trials
- An analytic method for randomized trials with informative censoring. I
- Augmented Designs to Assess Immune Response in Vaccine Trials
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- Evaluating the Predictiveness of a Continuous Marker
- Principal stratification in causal inference
Cited in
(72)- Assessing the value of a censored surrogate outcome
- Causal inference: a missing data perspective
- Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy
- Identification of causal effects within principal strata using auxiliary variables
- An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
- Bayesian methods for multiple mediators: relating principal stratification and causal mediation in the analysis of power plant emission controls
- Exploiting multiple outcomes in Bayesian principal stratification analysis with application to the evaluation of a job training program
- Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
- An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference
- Design and estimation for evaluating principal surrogate markers in vaccine trials
- Using Secondary Outcomes to Sharpen Inference in Randomized Experiments With Noncompliance
- Surrogate measures and consistent surrogates
- Comparing biomarkers as principal surrogate endpoints
- Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
- The Evaluation of Multiple Surrogate Endpoints
- Principal stratification in causal inference
- Augmented designs to assess principal strata direct effects
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
- On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints
- A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
- A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint
- A multiple imputation approach for the evaluation of surrogate markers in the principal stratification causal inference framework
- Comparing biomarkers as trial level general surrogates
- Principal causal effect identification and surrogate end point evaluation by multiple trials
- Assessing vaccine effects in repeated low-dose challenge experiments
- Discussion on ``Surrogate measures and consistent surrogates
- Discussion on ``Surrogate measures and consistent surrogates
- Rejoinder on: ``Surrogate measures and consistent surrogates
- A unified evaluation of differential vaccine efficacy
- Evaluation of longitudinal surrogate markers
- Robust methods to correct for measurement error when evaluating a surrogate marker
- Solutions for Surrogacy Validation with Longitudinal Outcomes for a Gene Therapy
- Testing for Heterogeneity in the Utility of a Surrogate Marker
- Assessing heterogeneity in surrogacy using censored data
- Surrogacy validation for time-to-event outcomes with illness-death frailty models
- Semiparametric pseudo-score and pseudo-likelihood for evaluating correlate of protection in vaccine trials
- Quantifying the feasibility of shortening clinical trial duration using surrogate markers
- Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm
- Estimation of the proportion of treatment effect explained by a high-dimensional surrogate
- Using principal stratification in analysis of clinical trials
- Using a surrogate with heterogeneous utility to test for a treatment effect
- Flexible evaluation of surrogate markers with Bayesian model averaging
- An information-theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: application to vaccine evaluation
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials
- Identification and estimation of causal effects in the presence of confounded principal strata
- Principal stratification with continuous post-treatment variables: nonparametric identification and semiparametric estimation
- Avoiding the surrogate paradox: an empirical framework for assessing assumptions
- Evaluating causal effects on time-to-event outcomes in an rct in oncology with treatment discontinuation
- Semiparametric localized principal stratification analysis with continuous strata
- Surrogates of protection in repeated low-dose challenge experiments
- Model-free approach to evaluate a censored intermediate outcome as a surrogate for overall survival
- RISE: two-stage rank-based identification of high-dimensional surrogate markers applied to vaccinology
- Bayesian nonparametric trees for principal causal effects
- Surrogate marker evaluation: a tutorial using R
- Surrogate endpoints in drug development: a review of statistical and regulatory perspectives and applications
- Robust evaluation of longitudinal surrogate markers with censored data
- Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints
- Power/sample size calculations for assessing correlates of risk in clinical efficacy trials
- Latent class instrumental variables: a clinical and biostatistical perspective
- A general framework to assess complex heterogeneity in the strength of a surrogate marker
- Links between causal effects and causal association for surrogacy evaluation in a Gaussian setting
- A method to address between-subject heterogeneity for identification of principal surrogate markers in repeated low-dose challenge HIV vaccine studies
- Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial
- Evaluating surrogate marker information using censored data
- Assessing a surrogate predictive value: a causal inference approach
- Towards optimal use of surrogate markers to improve power
- Evaluating time-to-event surrogates for time-to-event true endpoints: an information-theoretic approach based on causal inference
- A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference
- Causal inference over a subpopulation: the effect of malaria vaccine in women during pregnancy
- A causal framework for surrogate endpoints with semi-competing risks data
- Causal measures of the treatment effect captured by candidate surrogate endpoints
This page was built for publication: Evaluating Candidate Principal Surrogate Endpoints
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3549407)
